Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sinobiopharm.com
(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
IND APPLICATION OF TQF3250 CAPSULES "GLP-1 RECEPTOR AGONIST" ACCEPTED BY NMPA

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that the Investigational New Drug (IND) application for the TQF3250 capsules "GLP-1 receptor agonist (GLP-1RA)", a National Class 1 innovative drug intended for the treatment of type 2 diabetes and independently developed by the Group, has been accepted by the National Medical Products Administration (NMPA) of China.

TQF3250 is an orally administered small-molecule biased GLP-1RA. By selectively activating the cAMP-biased GLP-1R signaling pathway, it effectively promotes insulin secretion while reducing β-arrestin recruitment and receptor endocytosis, thereby prolonging the duration of therapeutic effect.

Preclinical studies in mouse models show that TQF3250 significantly improved glucose tolerance at doses as low as 1 mg/kg, exhibiting potency comparable to similar drug Orforglipron and demonstrating potent hypoglycemic effects. In the crab-eating macaque model, TQF3250 achieved a no-observed-adverse-effect level (NOAEL) of 24 mg/kg/day with no significant cardiac toxicity or genotoxicity risks observed, indicating a favourable safety profile.

Third-party statistics show that the global GLP-1RA market surpassed US$50 billion in 2024 and is projected to exceed US$150 billion by 2031. While the GLP-1RA market is currently dominated by injectable formulations, TQF3250, as an oral capsule formulation, has the following advantages:

1. **Convenient administration:** Oral administration can significantly improve patient compliance;

2. **Storage stability:** As demonstrated by tests, the formulation remains stable for 24 months at 25ºC;

3. **Metabolic safety:** The formulation is primarily metabolized by CYP3A enzymes, posing low risk of drug interactions.

To date, only one orally administered GLP-1RA has been approved for marketing globally. The Group will expedite the clinical development of TQF3250 to provide type 2 diabetes patients with a more convenient and effective treatment option.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 22 September 2025

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.